Suppr超能文献

早期临床淋巴结阴性乳腺癌中的类固醇受体、pS2和组织蛋白酶D

Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.

作者信息

Stonelake P S, Baker P G, Gillespie W M, Dunn J A, Spooner D, Morrison J M, Bundred N J, Oates G D, Lee M J, Neoptolemos J P

机构信息

University Department of Surgery, Queen Elizabeth Hospital, Birmingham, U.K.

出版信息

Eur J Cancer. 1994;30A(1):5-11. doi: 10.1016/s0959-8049(05)80008-5.

Abstract

Four oestrogen-regulated proteins of reported prognostic value, oestrogen receptor (ER), progesterone receptor (PR), pS2 and cathepsin D (Cat D), have been quantified by immunoassays, and the latter studied by immunohistochemistry (IHC) in primary tumours from clinically node-negative early breast cancer patients, entered into a trial of breast conservation therapy in which all the patients received adjuvant tamoxifen. ER, PR and pS2 significantly co-correlated but none correlated with Cat D. ER, PR and pS2, but not Cat D, were significantly associated with tumour size and grade, although Cat D tended to show an inverse relationship with the latter. Cat D (radioimmunoassay) in pmol/mg significantly correlated with the IHC score for Cat D in carcinoma cells as well as the number of Cat D-expressing macrophages. At a median follow-up of only 16 months, recurrence was significantly more common in patients with tumours having negative status for ER, PR and pS2 but was not associated with Cat D status.

摘要

已通过免疫测定法对四种据报道具有预后价值的雌激素调节蛋白,即雌激素受体(ER)、孕激素受体(PR)、pS2和组织蛋白酶D(Cat D)进行了定量,并通过免疫组织化学(IHC)对临床淋巴结阴性的早期乳腺癌患者原发肿瘤中的组织蛋白酶D进行了研究,这些患者进入了保乳治疗试验,所有患者均接受辅助他莫昔芬治疗。ER、PR和pS2显著共同相关,但均与Cat D不相关。ER、PR和pS2与肿瘤大小和分级显著相关,但Cat D与肿瘤大小和分级不相关,尽管Cat D与肿瘤大小和分级呈负相关趋势。以皮摩尔/毫克为单位的Cat D(放射免疫测定法)与癌细胞中Cat D的免疫组织化学评分以及表达Cat D的巨噬细胞数量显著相关。在仅16个月的中位随访期内,ER、PR和pS2呈阴性的肿瘤患者复发更为常见,但与Cat D状态无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验